SIA
NWBO

Stancorp Investment Advisers’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Stancorp Investment Advisers’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$4K Hold
480
– – ﹤0.01% 576
2014
Q4 		$3K Buy
+480
New +$2.46K ﹤0.01% 604

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stancorp Investment Advisers's NWBO Position: Q1 2015 in Review

Stancorp Investment Advisers held its Northwest Biotherapeutics, Inc. Common stock (NWBO) position steady in Q1 2015 at 480 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #576.

Stancorp Investment Advisers first reported a position in NWBO in Q4 2014 and has held it in 2 quarters since. 75 funds tracked by Wall St. Rank hold NWBO as of Q1 2015.

  • Stancorp Investment Advisers held 480 shares of Northwest Biotherapeutics, Inc. Common stock worth $4K as of Q1 2015.
  • Stancorp Investment Advisers left its Northwest Biotherapeutics, Inc. Common stock share count unchanged in Q1 2015.
  • Northwest Biotherapeutics, Inc. Common stock made up ﹤0.01% of Stancorp Investment Advisers's portfolio in Q1 2015, its #576 holding.
  • Stancorp Investment Advisers first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2014 and has held it in 2 quarters since.
  • 75 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q1 2015.

Based on Stancorp Investment Advisers's 13F filing for Q1 2015, filed 13 May 2015.